Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Dermatologic ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Hirsutism: implications, etiology, and management.Am J Obstet Gynecol. 1981; 140: 815-830
- The diagnosis and management of hirsutism.Semin Reprod Med. 2003; 21: 285-293
- An overview of unwanted female hair.Br J Dermatol. 2011; 165: 19-23
- Diagnosis of hair disorders.Semin Cutan Med Surg. 2009; 28: 33-38
- European consensus on the evaluation of women presenting with excessive hair growth.Eur J Dermatol. 2009; 19: 597-602
- The evaluation and management of hirsutism.Obstet Gynecol. 2003; 101: 995-1007
- Differential diagnosis of clinically evident hyperandrogenism: experience with over 1000 consecutive patients.Fertil Steril. 2001; 76: S111
- A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenic alopecia.Clin Endocrinol. 1994; 41: 231-236
- Etiologic review of hirsutism in 250 patients.Arch Med Res. 1994; 25: 311-314
- Total testosterone and DHEAS levels as predictors of androgen-secreting neoplasms: a populational study.Gynecol Endocrinol. 1999; 13: 1-7
- Quality of life of hirsute women.Postgrad Med J. 1993; 69: 186-189
- Psychological morbidity in women referred for treatment of hirsutism.J Psychosom Res. 1993; 37: 615-619
- Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome.Eur J Endocrinol. 2005; 153: 853-860
- Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels.Fertil Steril. 2009; 92: 626-634
- Puberty and ovarian function in girls with type 1 diabetes mellitus.Horm Res. 2009; 71: 12-21
- The prevalence of androgen excess among patients with minimal unwanted hair growth.Am J Obstet Gynecol. 2004; 191: 1914-1920
- Idiopathic hirsutism.Endocr Rev. 2000; 21: 347-362
- The relationship of mild hirsutism or acne in women to androgens.Arch Dermatol. 1987; 123: 209-212
- Idiopathic hirsutism: an uncommon cause of hirsutism in Alabama.Fertil Steril. 1998; 70: 274-278
- Prevalence of idiopathic hirsutism.Eur J Endocrinol. 1998; 139: 421-423
- Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: a common endocrinopathy with distinct pathophysiologic features.Am J Obstet Gynecol. 2012; 147: 90-101
- Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society Clinical Practice Guideline.J Clin Endocrinol Metab. 2008; 93: 1105-1120
- Adrenocortical carcinoma: clinical and laboratory observations.Cancer. 2000; 88: 711-736
- Medical treatment of hirsutism.Dermatol Ther. 2008; 21: 329-339
- Cyproterone acetate for hirsutism.Cochrane Database Syst Rev. 2003; (CD003053)
- A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole and cyproterone acetate-oestrogen regimens in the treatment of hirsutism.J Clin Endocrinol Metab. 1999; 84: 1304-1310
- Progestogens with antiandrogenic properties.Drugs. 2003; 63: 463-492
- Predictors of clinical response in hirsute women treated with spironolactone.Fertil Steril. 1991; 55: 1076-1081
- Antiandrogens for the treatment of hirsutism: a systematic review and meta-analyses of randomized controlled trials.J Clin Endocrinol Metab. 2008; 93: 1153-1160
- Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.Cochrane Database Syst Rev. 2003; (CD000194)
- Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-label study.J Clin Endocrinol Metab. 2004; 89: 2756-2762
- Treatment of hirsutism with combied pill containing drospirenone.Gynecol Endocrinol. 2008; 24: 220-223
- New alternative treatment in hirsutism: bicalutamide 25 mg/day.Gynecol Endocrinol. 2002; 16: 63-66
- Comparison of finasteride versus flutamide in the treatment of hirsutism.Eur J Endocrinol. 1999; 141: 361-367
- Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study.Fertil Steril. 2005; 84: 1693-1697
- The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism.Gynecol Endocrinol. 2003; 17: 57-63
- Percutaneous absorption and pharmacokinetics of eflornithine HCL 13.9% cream in women with unwanted facial hair.J Clin Pharmacol. 2001; 41: 972-978
- Human dermal safety studies with eflornithine HCl 13.9% cream (Vaniqa), a novel treatment for excessive facial hair.Curr Med Res Opin. 2001; 16: 235-244
- Topical eflornithine.Am J Clin Dermatol. 2001; 2: 197-201
- Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair.Int J Dermatol. 2007; 46: 94-98
- Eflornithine cream combined with laser therapy in the management of unwanted facial hair growth in women: a randomized trial.Dermatol Surg. 2006; 32: 1237-1243
- A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women.J Am Acad Dermatol. 2007; 57: 54-59
- Insulin-sensitizing drugs (metformin, troglitazone, rosiglitazone, pioglitazone, d-chiroinositol) for polycystic ovary syndrome.Cochrane Database Syst Rev. 2003; (CD003053)
- Insulin sensitizers for the treatment of hirsutism: as systematic review and meta-analysis of randomized controlled trials.J Clin Endocrinol Metab. 2008; 93: 1135-1142
- Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.N Engl J Med. 2007; 356: 2457-2471
- Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease.Endocr J. 2005; 52: 299-308
- The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.Gynecol Endocrinol. 2005; 21: 154-160
- Methods of hair removal.J Am Acad Dermatol. 1999; 40: 143-155
- Hair reduction: 48 months of experience with 800 nm diode laser.J Cosmet Laser Ther. 2003; 5: 146-149
- Hair remocal using a long-pulsed alexandrite laser.Dermatol Clin. 1999; 17: 387-399
- Optimizing treatment parameters for hair removal using a topical carbon-based solution and 1064-nm Q-switched neodymium: YAG laser energy.Arch Dermatol. 1997; 133: 1546-1549
- Laser hair reduction in the hirsute patient: a critical assessment.Hum Reprod Update. 2002; 8: 169-181
- Polycystic ovary syndrome.Obstet Gynecol. 2004; 103: 181-193
- Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.Cochrane Database Syst Rev. 2012; 5 (CD003053)
- The investigation and management.J Fam Plann Reprod Health Care. 2012; 38: 182-186
Article info
Publication history
Published online: October 12, 2012
Footnotes
The author declares no conflicts of interest.
Identification
Copyright
© 2013 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
